The Biological Properties of Bacterial Toxins

Knowledge of the biological properties of bacterial toxins is constantly being updated. Over the past two decades, the research interest has shifted from natural toxins to their genetically modified derivatives. The purpose of the work is to summarize the knowledge of the biological properties of bacterial toxins accumulated in the English-language scientific literature in recent years. The research method is analytical. The source base for the research is Englishlanguage scientific literature, accessible through the global Internet. Results. The work examines: the organization and general mechanism of action of bacterial toxin molecules; the reliability of their toxicity indicators given in the scientific literature; toxic effects of toxins of various groups, differing in their mechanism of action; obtaining hybrid and modified toxins; identification of artificial toxins. Conclusions. Among bacterial toxins, binary toxins are the most dangerous. The binary composition of bacterial exotoxins, a good understanding of their subunits, functional domains, assembly mechanisms and intracellular action, make it possible to modify them in the direction of changing the range of targets, toxicity, mechanism of damaging action and immunogenicity. To identify genetically modified toxins, poorly studied analogues and isoforms of natural toxins, special programs based on machine learning can be used.

1. Vertiev JuV. Bacterial toxins: their biological essence and origin. Zh Mikrobiol Epidemiol Immunobiol. 1996;(3):43–6 (in Russian).

2. Buharin OV, Litvin VJu. Pathogenic bacteria in natural ecosystems. Ekaterinburg; 1997 (in Russian).

3. Bezrukov SM, Nestorovich EM. Inhibiting bacterial toxins by channel blockage. Pathog Dis. 2016;74(2):ftv113. https://doi.org/10.1093/femspd/ftv113

4. Rudkin JK, McLoughlin RM, Preston A, Massey RC. Bacterial toxins: Offensive, defensive, or something else altogether? PLoS Pathog. 2017;13(9):e1006452. https://doi.org/10.1371/journal.ppat.1006452

5. Biernbaum EN, Kudva IT. AB5 Enterotoxin-Mediated Pathogenesis: Perspectives Gleaned from Shiga Toxins. Toxins (Basel). 2022;14(1):62. https://doi.org/10.3390/toxins14010062

6. Márquez-López A, Fanarraga ML. AB Toxins as High-Affinity Ligands for Cell Targeting in Cancer Therapy. Int J Mol Sci. 2023;24(13):11227. https://doi.org/10.3390/ijms241311227

7. Bonifacino JS, Rojas R. Retrograde transport from endosomes to the trans-Golgi network. Nat Rev Mol Cell Biol. 2006;7:568–79. https://doi.org/10.1038/nrm1985

8. Sandvig K, Skotland T, van Deurs B, Klokk TI. Retrograde transport of protein toxins through the Golgi apparatus. Histochem Cell Biol. 2013;140:317–326.

9. Lukassen S, Chua R, Trefzer T, Kahn NC, Schneider MA, Muley Th, et al. SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. EMBO J. 2020;39(10):e105114. https://doi.org/10.15252/embj.20105114

10. Finlay B, Falkow S. Common themes in microbial pathogenicity. Microbiol Rev. 1997. 53(2);210–30. https://doi.org/10.1128/mr.53.2.210-230.1989

11. Sanyaolu A, Okorie Ch, Marinkovic A, Haider H. The emerging SARS-CoV-2 variants of concern. Ther Adv Infect Dis. 2021. https://doi.org/10.1177/20499361211024372

12. Littler DR, Ang SY, Moriel DG, Kocan M, Kleifeld O, Johnson MD, et al. Structure-function analyses of a pertussis-like toxin from pathogenic Escherichia coli reveal a distinct mechanism of inhibition of trimeric G-proteins. J Biol Chem. 2017;292(36):15143–58. https://doi.org/10.1074/jbc.M117.796094

13. Lemichez E, Flatau G, Bruzzone M, Boquet P, Gauthier M. Molecular localization of the Escherichia coli cytotoxic necrotizing factor CNF1 cell-binding and catalytic domains. Mol Microbiol. 1997;24(7):1061–70. https://doi.org/10.1046/j.1365-2958.1997.4151781.x

14. Petosa C, Collier P, Klimpel KR, Leppla SH, Liddington RC. Crystal structure of the anthrax toxin protective antigen. Nature. 1997;385(6619):833–38. https://doi.org/10.1038/385833a0

15. Trescos Y, Tournier J-N. Cytoskeleton as an emerging target of anthrax toxins. Toxins. 2012;4:83–97. https://doi.org/10.3390/toxins4020083

16. Zuverink M, Barbieri JT. Protein Toxins That Utilize Gangliosides as Host Receptors. Prog Mol Biol Transl Sci. 2018;156:325–54. https://doi.org/10.1016/bs.pmbts.2017.11.010

17. Uchida I, Ishihara R, Tanaka K, Hata E, Makino SI, Kanno T, et al. Salmonella enterica serotype Typhimurium DT104 ArtA-dependent modification of pertussis toxin-sensitive G proteins in the presence of [32P] NAD. Microbiology (Reading). 2009;155(Pt 11):3710–18. https://doi.org/10.1099/mic.0.028399-0

18. Pavlik BJ, Hruska EJ, Van Cott KE, Blum PH. Retargeting the Clostridium botulinum C2 toxin to the neuronal cytosol. Sci Rep. 2016;6:23707. https://doi.org/10.1038/srep23707

19. Friebe S, van der Goot F, Bürgi J. The Ins and Outs of Anthrax Toxin. Toxins. 2016;8:69. https://doi.org/10.3390/toxins8030069

20. Rossetto O, Montecucco C. Tables of Toxicity of Botulinum and Tetanus Neurotoxins. Toxins (Basel). 2019;11(12):686. https://doi.org/10.3390/toxins11120686

21. Schmitt CK, Meysick KC, Brien AD. Bacterial toxins: friends or foes? Emerg Infect Dis. 1999;5(2):224–34. https://doi.org/10.3201/eid0502.990206

22. Dal Peraro M, van der Goot FG. Pore-forming toxins: ancient, but never really out of fashion. Nat Rev Microbiol. 2016;14(2):77–92. https://doi.org/10.1038/nrmicro.2015.3

23. Berube BJ, Wardenburg J. Staphylococcus aureus α-toxin: nearly a century of intrigue. Toxins (Basel). 2013;5(6):1140–66. https://doi.org/10.3390/toxins5061140

24. Li Y, Li Y, Mengist HM, Zhang C, Wang B, Li T, et al. Structural Basis of the Pore-Forming Toxin/ Membrane. Interaction Toxins (Basel). 2021;13(2):128. https://doi.org/10.3390/toxins13020128

25. Bischofberger M, Iacovache I, van der Goot FG. Pathogenic pore-forming proteins: function and host response. Cell Host Microbe. 2012;12(3):266–75. https://doi.org/10.1016/j.chom.2012.08.005

26. Xiang Y, Yan C, Guo X, Zhou K, Li S, Gao Q, et al. Host-derived, pore-forming toxin-like protein and trefoil factor complex protects the host against microbial infection. Proc Natl Acad Sci USA. 2014;111(18):6702–7. https://doi.org/10.1073/pnas.1321317111

27. Galinier R, Portela J, Moné Y, Allienne JF, Henri H, Delbecq S, et al. Biomphalysin, a new β pore-forming toxin involved in Biomphalaria glabrata immune defense against Schistosoma mansoni. PLoS Pathog. 2013;9(3):e1003216. https://doi.org/10.1371/journal.ppat.1003216

28. Ulhuq FR, Mariano G. Bacterial pore-forming toxins. Microbiology (Reading). 2022;168(3):001154. https://doi.org/10.1099/mic.0.001154

29. Dudev T, Lim C. Ion selectivity in the selectivity filters of acidsensing ion channels. Sci Rep. 2015;5:7864. https://doi.org/10.1038/srep07864

30. Bhakdi S, Bayley H, Valeva A, Walev I, Walker B, Kehoe M, et al. Staphylococcal alpha-toxin, streptolysin-O and Escherichia coli hemolysin: prototypes of pore-forming bacterial cytolysins. Arch Microbiol. 1996;165(1):73–9. https://doi.org/10.1007/s002030050300

31. Bhakdll S, Tranum-Jensen J. Alpha-toxin of Staphylococcus aureus. Microbiol Rev. 1991;55(4):733–51. https://doi.org/10.1128/mr.55.4.733-751.1991

32. Jushchuk ND, Kulagina MT. Diphtheria: clinical course, diagnosis and treatment. Russkij Medicinskij Zhurnal. 1997;(4):208–17 (in Russian).

33. Yamaizumi M, Mekada E, Uchida T, Okada Y. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell. 1978;15(1):245-50. https://doi.org/10.1016/0092-8674(78)90099-5

34. Liu PV. The roles of various fractions of Pseudomonas aeruginosa in its pathogenesis. 3. Identity of the lethal toxins produced in vitro and in vivo. J Infect Dis. 1966;116(4):481–89. https://doi.org/10.1093/infdis/116.4.481

35. Liu PV. Toxins of Pseudomonas aeruginosa. In: Pseudomonas aeruginosa (clinical manifestation and current therapy). Doggett RG, Ed. N.Y.; 1979. P. 90–135.

36. Мороз АФ, Анциферова НГ, Баскакова НИ. Синегнойная инфекция. Мороз АФ, ред. М.; 1988. Moroz AF, Anciferova NG, Baskakova NI. Pseudomonas infection. Moroz AF, Ed. Moscow; 1988 (in Russian).

37. McCluskey AJ, Collier RJ. Receptor-directed chimeric toxins created by sortase-mediated protein fusion. Mol Cancer Ther. 2013;12(10):2273–81. https://doi.org/10.1158/1535-7163.MCT-13-0358

38. Lazareva AV, Chebotar' IV, Kryzhanovskaja OA, Chebotar' VI, Majanskij NA. Pseudomonas aeruginosa: Pathogenicity, Pathogenesis and Diseases. Klin mikrobiol antimikrob himioter. 2015;17(3):170–86 (in Russian).

39. Kreitman RJ, Siegall CB, Chaudhary VK, FitzGerald DJ, Pastan I. Properties of chimeric toxins with two recognition domains: interleukin 6 and transforming growth factor alpha at different locations in Pseudomonas exotoxin. Bioconjug Chem. 1992;3(1):63–8. https://doi.org/10.1021/bc00013a010

40. Tian S, Zhou N. Gaining New Insights into Fundamental Biological Pathways by Bacterial Toxin-Based Genetic Screens. Bioengineering (Basel). 2023;10(8):884. https://doi.org/10.3390/bioengineering10080884

41. Chan YS, Ng TB. Shiga toxins: From structure and mechanism to applications. Appl Microbiol Biotechnol. 2016;100:1597–610. https://doi.org/10.1007/s00253-015-7236-3

42. De SN. Enterotoxicity of bacteria-free culture-filtrate of Vibrio cholera. Nature. 1959;183(4674):1533–4. https://doi.org/10.1038/1831533a0

43. Bharati K, Ganguly NK. Cholera toxin: a paradigm of a multifunctional protein. Indian J Med Res. 2011;133(2):179–87. PMID: 21415492.

44. He X, Yang J, Ji M, Chen Y, Chen Y, Li H, et al. Potential delivery system based on cholera toxin: A macromolecule carrier with multiple activities. J Control Release. 2022;343:551–63. https://doi.org/10.1016/j.jconrel.2022.01.050

45. Weiss AA, Hewlett EL, Myers GA, Falkow S. Pertussis toxin and extracytoplasmic adenylate cyclase as virulence factors of Bordetella pertussis. J Infect Dis. 1984;150:219–22. https://doi.org/10.1093/infdis/150.2.2194

46. Gregg KA, Merkel TJ. Pertussis Toxin: A Key Component in Pertussis Vaccines? T oxins ( Basel). 2019;11(10):557. https://doi.org/10.3390/toxins11100557

47. Ernst K. Novel Strategies to Inhibit Pertussis Toxin. Toxins (Basel). 2022;14(3):187. https://doi.org/10.3390/toxins14030187

48. Carbonetti NH. Contribution of Pertussis Toxin to the Pathogenesis of Pertussis Disease. Pathog Dis. 2015;73:ftv073. https://doi.org/10.1093/femspd/ftv073

49. Kilgore PE, Salim AM, Zervos MJ, Schmitt H.-J. Pertussis: Microbiology, Disease, Treatment, and Prevention. Clin Microbiol Rev. 2016;29:449–86. https://doi.org/10.1128/CMR.00083-15

50. Scanlon K, Skerry C, Carbonetti N. Association of Pertussis Toxin with Severe Pertussis Disease. Toxins (Basel). 2019;11(7):373. https://doi.org/10.3390/toxins11070373

51. Saitoh M, Tanaka K, Nishimori K, Makino SI, Kanno T, Ishihara R, et al. The artAB genes encode a putative ADP-ribosyltransferase toxin homologue associated with Salmonella enterica serovar Typhimurium DT104. Microbiology. 2005;151:3089–96. https://doi.org/10.1099/mic.0.27933-0

52. Johnson TJ, DebRoy C, Belton S, Williams ML, Lawrence M, Nolan LK, et al. Pyrosequencing of the Vir Plasmid of Necrotoxigenic Escherichia coli. Vet Microbiol. 2010;144(1–2):100–9. https://doi.org/10.1016/j.vetmic.2009.12.022

53. Scuron MD, Boesze-Battaglia K, Dlakić M, Shenker BJ. The Cytolethal Distending Toxin Contributes to Microbial Virulence and Disease Pathogenesis by Acting As a Tri-Perditious Toxin. Front Cell Infect Microbiol. 2016;6:168. https://doi.org/10.3389/fcimb.2016.00168

54. Lai YR, Chang YF, Ma J, Chiu CH, Kuo ML, Lai CH. From DNA Damage to Cancer Progression: Potential Effects of Cytolethal Distending Toxin. Front Immunol. 2021;12:760451. https://doi.org/10.3389/fimmu.2021.760451

55. Pickett CL, Cottle DL, Pesci EC, Bikah G. Cloning, sequencing, and expression of the Escherichia coli cytolethal distending toxin genes. Infect Immun. 1994;62:1046–51. https://doi.org/10.1128/iai.62.3.1046-1051.1994

56. Grasso F, Frisan T. Bacterial Genotoxins: Merging the DNA Damage Response into Infection Biology. Biomolecules. 2015;5(3):1762–82. https://doi.org/10.3390/biom5031762

57. Ceelen LM, Decostere A, Ducatelle R, Haesebrouck F. Cytolethal distending toxin generates cell death by inducing a bottleneck in the cell cycle. Microbiol Res. 2006;161(2):109–20. https://doi.org/10.1016/j.micres.2005.04.002

58. Guerra L, Cortes-Bratti X, Guidi R, Frisan T. The biology of the cytolethal distending toxins. Toxins (Basel). 2011;3(3):172–90. https://doi.org/10.3390/toxins3030172

59. Nougayrede JP, Taieb F, De Rycke J, Oswald E. Cyclomodulins: Bacterial Effectors That Modulate the Eukaryotic Cell Cycle. Trends Microbiol. 2005;13(3):103–10. https://doi.org/10.1016/j.tim.2005.01.002

60. Pirazzini M, Henke T, Rossetto O, Mahrhold S, Krez N, Rummel A, et al. Neutralisation of specific surface carboxylates speeds up translocation of botulinum neurotoxin type B enzymatic domain. FEBS Lett. 2013;587(23):3831–86. https://doi.org/10.1016/j.febslet.2013.10.010

61. Contreras E, Masuyer G, Qureshi N, Chawla S, Dhillon HS, Lee HL, Chen J, et al. A neurotoxin that specifically targets Anopheles mosquitoes. Nat Commun. 2019;10(1):2869. https://doi.org/10.1038/s41467-019-10732-w

62. Peck MW, Smith TJ, Anniballi F, Austin JW, Bano L, Bradshaw M, et al. Historical perspectives and guidelines for botulinum neurotoxin subtype nomenclature. Toxins. 2017;9:38. https://doi.org/10.3390/toxins9010038

63. Rosales RL, Bigalke H, Dressler D. Pharmacology of botulinum toxin: differences between type A preparations. Eur J Neurol. 2006;Suppl 1:2–10. https://doi.org/10.1111/j.1468-1331.2006.01438.x

64. Megighian A, Pirazzini M, Fabris F, Rossetto O, Montecucco C. Tetanus and tetanus neurotoxin: from peripheral uptake to central nervous tissue targets. J Neurochem. 2021;158:1244–1253. https://doi.org/10.1111/jnc.15330

65. Rao AK, Sobel J, Chatham-Stephens K, Luquez C. Clinical guidelines for diagnosis and treatment of botulism. MMWR Recommendations Rep. 2021;70:1–30. https://www.cdc.gov/mmwr/volumes/70/rr/rr7002a1.htm

66. Плецитный ДФ. Экспериментальное изучение патогенеза столбнячной интоксикации. М.; 1958. Plecitnyj DF. Experimental study of the pathogenesis of tetanus intoxication. Moscow; 1958 (in Russian).

67. Arnon S. Human tetanus and human botulism. In: The clostridia: molecular biology and pathogenesis. Rood JI, McClane BA, Songer JG, Titball RW, Eds. San Diego: Academic Press; 1997. P. 95–115. https://doi.org/10.1146/annurev-biochem-013118-111654

68. Dong M, Masuyer G, Stenmark P. Botulinum and tetanus neurotoxins. Annu Rev Biochem. 2019;88:811–37. https://doi.org/10.1146/annurev-biochem-013118-111654

69. Halpern J, Neale E. Neurospecific binding, internalization and retrograde axonal transport. Curr Top Microbiol Immunol. 1995;195(1):221–41. https://doi.org/10.1007/978-3-642-85173-5_10

70. Doxey AC, Mansfeld MJ, Montecucco C. Discovery of novel bacterial toxins by genomics and computational biology. Toxicon. 2018;147:2–12. https://doi.org/10.1016/j.toxicon.2018.02.002

71. Montecucco C, Molgó J. Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol. 2005;5(3):274–279. https://doi.org/10.1016/j.coph.2004.12.006

72. Shikhkerimov RK, Istomina EV. Recombinant botulinum toxin as a new stage in the development of botulinum toxin therapy. Possibilities and perspectives of use in neurological practice. Neurology, Neuropsychiatry, Psychosomatics. 2022;14(6): 103–9 (in Russian). https://doi.org/10.14412/2074-2711-2022-6-103-109

73. White J, Herman A, Pullen AM, Hashimoto K, Sugaya K, Kubo M, et al. The Vβ-specific superantigen staphylococcal enterotoxin B: Stimulation of mature T cells and clonal deletion in neonatal mice. Cell. 1989;56:27–35. https://doi.org/10.1016/0092-8674(89)90980-x

74. Schlievert P. Searching for superantigens. Immunol Infect. 1997;26(2):283–90. https://doi.org/10.3109/08820139709048934

75. Blank C, Luz A, Bendigs S, Erdmann A, Wagner H, Heeg K. Superantigen and endotoxin synergize in the induction of lethal shock. Eur J Immunol. 1997;27(4):825–33. https://doi.org/10.1002/eji.1830270405

76. Sutkowski N, Conrad B, Thorley-Lawson D.A, Huber BT. Epstein-Barr virus transactivates the human endogenous retrovirus HERV-K18 that encodes a superantigen. Immunity. 2001;15(4):579–89. https://doi.org/10.1016/s1074-7613(01)00210-2

77. Efremenko E, Aslanli A, Lyagin I. Advanced Situation with Recombinant Toxins: Diversity, Production and Application Purposes. Int J Mol Sci. 2023;24(5):4630. https://doi.org/10.3390/ijms24054630

78. Deist BR, Rausch MA, Fernandez-Luna MT, Adang MJ, Bonning BC. Bt toxin modification for enhanced efficacy. Toxins (Basel). 2014;6(10):3005–27. https://doi.org/10.3390/toxins6103005

79. Shamsutdinov AF, Tjurin JuA. Protein toxins of Staphylococcus aureus. Zh Mikrobiol Epidemiol Immunobiol. 2014;91(2):113–20 (in Russian).

80. Wu SJ, Koller CN, Miller DL, Bauer LS, Dean DH. Enhanced toxicity of Bacillus thuringiensis Cry3A deltaendotoxin in coleopterans by mutagenesis in a receptor binding loop. FEBS Lett. 2000;473:227–32. https://doi.org/10.1016/s0014-5793(00)01505-2

81. Liu XS, Dean DH. Redesigning Bacillus thuringiensis Cry1Aa toxin into a mosquito toxin. Prot Eng Design Selec. 2006;19:107–11. https://doi.org/10.1093/protein/gzj009

82. Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999; 53(7):1431–38. https://doi.org/10.1212/wnl.53.7.1431

83. Pappert EJ, Germanson T. Myobloc/Neurobloc European Cervical Dystonia Study Group. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial. Mov Disord. 2008;23(4):510–17. https://doi.org/10.1002/mds.21724

84. Tao L, Peng L, Berntsson RP, Liu SM, Park S, Yu F, et al. Engineered botulinum neurotoxin B with improved efficacy for targeting human receptors. Nat Commun. 2017;8(1):53. https://doi.org/10.1038/s41467-017-00064-y

85. Antignani A, Ho E, Bilotta MT, Qiu R, Sarnvosky R, FitzGerald DJ. Targeting Receptors on Cancer Cells with Protein Toxins. Biomolecules. 2020;10(9):1331. https://doi.org/10.3390/biom10091331

86. Kiyokawa T, Shirono K, Hattori T, Nishimura H, Yamaguchi K, Nichols JC, et al. Cytotoxicity of interleukin 2-toxin toward lymphocytes from patients with adult T-cell leukemia. Cancer Res. 1989;49(14):4042–46. PMID: 2786749.

87. Ardini M, Vago R, Fabbrini MS, Ippoliti R. From Immunotoxins to Suicide Toxin Delivery Approaches: Is There a Clinical Opportunity? Toxins (Basel). 2022;14(9):579. https://doi.org/doi:10.3390/toxins14090579

88. Contet A, Caussanel V, Beck A, Lowe P. Immunotoxines et immunocytokines [Immunotoxins and immunocytokines]. Med Sci (Paris). 2019;35(12):1054–61 (in French). https://doi.org/10.1051/medsci/2019205

89. Kreitman RJ, Siegall CB, Chaudhary VK, FitzGerald DJ, Pastan I. Properties of chimeric toxins with two recognition domains: interleukin 6 and transforming growth factor alpha at different locations in Pseudomonas exotoxin. Bioconjug Chem. 1992;3(1):63–8. https://doi.org/10.1021/bc00013a010

90. Fujinaga Y, Wolf AA, Rodighiero C. Gangliosides that associate with lipid rafts mediate transport of cholera and related toxins from the plasma membrane to endoplasmic reticulm. Mol Biol Cell. 2003;14:4783–93. http://dx.doi.org/10.1091/mbc

91. Guimaraes CP, Carette JE, Varadarajan M, Antos J, Popp MW, Spooner E, et al. Identification of host cell factors required for intoxication through use of modified cholera toxin. J Cell Biol. 2011;195(5):751–64. https://doi.org/10.1083/jcb.201108103

92. Avarbock AB, Loren AW, Park JY, Junkins-Hopkins JM, Choi J, Litzky LA, et al. Lethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gamma/delta T-cell lymphoma and occult cirrhosis. Am J Hematol. 2008;83(7):593–5. https://doi.org/10.1002/ajh.21180